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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the benefits and harms of prophylactic corticosteroids in children between birth and 18 years of age undergoing cardiac surgery
with cardiopulmonary bypass.
B A C K G R O U N D
Description of the condition
Paediatric heart surgery outcomes have improved markedly over
time as a result of marginal gains in training, technology and safety
systems (Brown 2015; Hoashi 2015; Jacobs 2016; NICOR2016).
This improvement has been particularly notable in the last 20
years: the publication of heart surgery outcomes after the Kennedy
Inquiry in the UK has been associated with a large increase in
survival for risk-adjusted surgery (Kennedy 2001; Grant 2013).
This has been mirrored worldwide (Brown 2015; Hoashi 2015;
Jacobs 2016). One area where there is still controversy is corti-
costeroid use. Paediatric heart surgery with the use of cardiopul-
monary bypass results in a systemic inflammatory response; corti-
costeroids have been widely used to mitigate the potential delete-
rious effects of this response. The surgical intervention for which
corticosteroids are used includes a variety of surgeries performed
on the heart and great vessels. In most cases this procedure aims
to correct congenital heart diseases (i.e. heart malformations that
the child is born with). In most cases (78% in the UK) (NICOR
2016), surgery will take place with the use Cardio-Pulmonary By-
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pass (CPB), also known as the ‘heart-lung machine’. Cannulae are
placed in the child’s major blood vessels and blood is channeled
out of the body, oxygen is added, carbon dioxide is removed and
the blood is then pumped back to the child’s body. This allows
the heart to be stopped and emptied of blood, thus allowing the
surgeon to operate in a bloodless field on a non-beating heart
(Barry 2015). As a result, there is activation of white blood cells
and platelets, as well as coagulation cascades (Tarnok 2001), with
the end signalling due to cytokines. Endothelial permeability in-
creases and parenchymal damage by free radicals occurs (Fudulu
2016; Pesonen 2016). Fluid leaks out of the circulation and into
the tissues, blood vessels vasodilate, hypovolaemia occurs and thus
poor blood pressure results. Many of the complications of car-
diac surgery, including multi-organ failure and death, result from
these mechanisms (Huffmyer 2015). Nevertheless, the impact of
prophylactic corticosteroids on clinical outcomes following heart
surgery on children remains unclear (Pasquali 2010; Keski-Nisula
2013).
Description of the intervention
Corticosteroids are hormones produced by the adrenal glands of
all mammals. In humans, the naturally-occurring corticosteroid is
called cortisol (hydrocortisone) (Gibbison 2013). Corticosteroids,
at a molecular level, are composed of a steroid backbone plus
various modifications to side-chains which can change the activ-
ity of the molecule. These modified side-chains are exploited by
drug manufacturers to modify the different properties of corticos-
teroids. Corticosteroids are fat soluble and therefore can pass freely
through cell walls to bind to their receptors, which are found inside
the target cells. Once they bind to their receptor, they travel into
the cell nucleus and act as a transcription factor, changing the ex-
pression of cellular proteins (Gibbison 2013). Synthetic and natu-
rally-occurring corticosteroids canbe given either before, during or
after cardiac surgery to elicit the beneficial effects described in the
next section (Toledo-Pereyra 1980; Pasquali 2010; Keski-Nisula
2015). In this context, they are usually given as intravenous drugs
and may be given as a bolus dose or by infusion. A variety of dif-
ferent steroid drugs are given. Frequently given drugs include dex-
amethasone (Lerzo 2011), methylprednisolone (Pasquali 2012),
and hydrocortisone (Robert 2015). The dose given in this context
is often equivalent to 10 to 20 times the total daily amount pro-
duced by adrenal glands in normal health.
How the intervention might work
Corticosteroids have several properties that make them attrac-
tive to give during the cardiac surgical peri-operative period. In
this context, their anti-inflammatory potential represents their
most desired feature. Cardiac surgery, with or without the use of
CPB, causes systemic inflammation by the earlier-describedmech-
anisms. This leads to poor perfusion which, coupled with the
effects of inflammatory mediators that occur directly to organs,
can lead to organ dysfunction and potentially death (Medzhitov
2008). To the clinician the most obvious organ dysfunction is al-
tered haemodynamics, which translates into the need to use sup-
port with inotropes and vasopressors postoperatively. The lungs
are also frequently affected: the fluid that leaks out of the ves-
sels and into the lung tissue and alveoli (air spaces) can have a
negative impact on ventilation and oxygenation, thus increasing
the need for mechanical ventilatory support. Many studies have
shown that corticosteroids reduce the concentrations and activity
of inflammatory mediators after cardiac surgery and increase the
concentrations of anti-inflammatory mediators, both locally in
the heart and systemically in the circulating plasma (Keski-Nisula
2013; Graham 2014; Dreher 2015; Amanullah 2016). Inducing
a shift of the inflammatory balance toward the anti-inflammatory
reaction is thought to, by extrapolation, reduce capillary leak, va-
sodilatation and organ dysfunction. Corticosteroids act directly to
vasoconstrict arterioles, as well as increasing salt and water reten-
tion in the kidney. These properties therefore improve blood pres-
sure and, potentially, organ perfusion in the short- and medium-
term. They also increase blood glucose levels by breaking down
fats, proteins and carbohydrates into their constituent building
blocks, which can be used for cellular energy.
Why it is important to do this review
Many corticosteroid studies are powered for and assess surrogate
outcomes, such as inflammatory mediator levels, rather than ob-
jective clinical outcomes. Corticosteroids have several deleterious
effects, which are traded off against the potentially beneficial effects
outlined earlier. The increase in blood glucose is associated with
less favourable outcomes after cardiac surgery (Pasquali 2010). In
the critically ill, they impair wound healing and cause immuno-
suppression, which may allow secondary infections to develop
(Pasquali 2012). Several studies also suggest that giving high-dose
corticosteroids to a child may impair long-term cognitive devel-
opment (Gibson 1993; Shinwell 2000; Yeh 2004). The neonatal
population represents a group of particular interest, as the evidence
for corticosteroid use remains inconclusive. Despite the lack of
certainty over its risks and benefits, its use is still common prac-
tice in many centres. There is no consensus about whether to give
corticosteroids or not (Fudulu 2018), or about the type of corti-
costeroids, dose regimen or when they may be beneficial, e.g. pre-
operatively versus intraoperatively versus postoperatively. There
are no national or international guidelines pertaining to corticos-
teroid use in the paediatric cardiac surgical perioperative period.
Practice varies both between and within institutions; patients in
one hospital may or may not receive corticosteroids depending on
the treating surgeon/anaesthetist/intensivist.
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O B J E C T I V E S
To assess the benefits and harms of prophylactic corticosteroids
in children between birth and 18 years of age undergoing cardiac
surgery with cardiopulmonary bypass.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include individually randomised controlled trials (RCTs),
including trials with more than two groups (e.g. multi-drug or
dose comparisons with a control group) but not ‘head-to-head’
trials without a placebo or no corticosteroids group. If we find
any cross-over randomised studies, we will only include the initial
period in our analyses. This Cochrane Review will examine the
effect of prophylactic corticosteroids in the perioperative period
and therefore it would be extremely difficult/impossible to design
a crossover study reporting clinical outcomes examining this inter-
vention. We will exclude any cluster-randomised studies we find;
theywould be subject to significant bias in this context because the
perioperative protocols and workloads will differ widely between
centres. Patients may therefore appear to be well-matched between
groups with regard to demographics, but not to many other areas.
We will include studies irrespective of their publication status.
We considered using large, published registry studies, but there is
likely to be a critical risk of confounding in these study groups
because the factors that cause clinicians to prescribe steroids pro-
phylactically are not captured due to the difficulty in defining
and documenting those reasons. Also, publications arising from
registries have reported the same outcomes as reported in RCTs
(e.g. mortality and hospital length of stay, so duplication of out-
come domain but with lower confidence in the effect estimate);
there would be more justification in including such studies if they
reported rare or long-term outcomes such as cognitive function,
which would complement outcomes reported in RCTs in an im-
portant way (Reeves 2013).
Types of participants
We will include children, from birth up to 18 years of age, includ-
ing preterm infants undergoing cardiac surgery with the use of car-
diopulmonary bypass. We will exclude studies that have included
participants with any of the following co-morbidities/characteris-
tics. If patient level data is available, we will only exclude patients
with the following criteria.
• Undergoing heart or lung transplantation, or both
• On pre-existing corticosteroids
• With abnormalities of the hypothalamic-pituitary-adrenal
(HPA) axis
• Given steroids at the time of cardiac surgery for indications
other than cardiac-surgery (e.g. allergy, bronchoconstriction)
If any study includes only a subset of eligible patients, we will
attempt to contact the study authors and obtain patient level data
or aggregated data for the eligible subgroup. If this is not possible,
then we will include a study if 80% or more of the participants
satisfy our eligibility criteria. We have set this threshold on the
assumption that up to 20% of ineligible participants would not
markedly bias the average estimate.We recognise that this rule rep-
resents an uncertain compromise; the number of potential studies
(and therefore participants) is likely to be small and this approach
trades off the risk of a slightly biased answer against an answer that
is too imprecise to be useful.
Types of interventions
Corticosteroids must be administered prophylactically, i.e. in an-
ticipation of adverse effects of cardiac surgery. The corticosteroids
canbe administered at any point in the preoperative, intraoperative
or postoperative period, but the time-point and regimen must be
prespecified and given to all eligible participants randomised to the
intervention arm (apart fromprotocol deviations).Wewill include
studies that include single and multiple doses and all types of cor-
ticosteroids administered via any route. Corticosteroids drugs in-
clude: hydrocortisone, dexamethasone, prednisolone, prednisone
and methylprednisolone or any other existing drugs/those to be
developed.
We will exclude studies that evaluate the effectiveness of ‘rescue’
corticosteroids (i.e. given in response to a clinical deterioration).
We will include studies that evaluate prophylactic corticosteroids
which allow for ‘rescue’ corticosteroids to be given to treat patients
who deteriorate.
We will include trials that compare any corticosteroids with
placebo or usual care without the use of corticosteroids. We will
also include multi-group studies comparing multiple doses, drugs
or regimen of corticosteroids against a placebo/no corticosteroids
control.
Types of outcome measures
Primary outcomes
• In-hospital, postoperative mortality
• Duration of postoperative mechanical ventilation (days)
An initial scoping search identified relatively few RCTs with rela-
tively small numbers of participants. There may not be sufficient
power when the data are pooled to detect a difference in postoper-
ative mortality due to the low baseline mortality rate. Therefore,
we have included a second, continuous primary outcome which, if
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reported for a similar number of participants, should have greater
power. Postoperative mechanical ventilation is an important out-
come due to the risk of complications both directly attributable
to the process itself and because, by definition, the patient must
be treated on an intensive care unit (a proxy marker for critical
illness) whilst receiving it.
Secondary outcomes
• Length of postoperative intensive care unit stay
• Length of postoperative hospital stay
• All-cause mortality at longest follow up
• Cardiovascular mortality at longest follow up
• Duration of postoperative inotropes/vasopressors
• Failure to separate from cardiopulmonary bypass
• Adverse events.
There is little consistency about the adverse events attributed to
steroid use that clinicians regard as important in terms of both type
of adverse event and the definitions and thresholds for reporting.
Therefore, the adverse events that are reported by clinical trials
are not consistent. They include outcomes such as infection, hy-
perglycaemia and poor wound healing. Such outcomes have never
been universally defined.We anticipate that it may not be possible
to fully provide adverse event data across the RCTs. We will how-
ever, collect all available data and review this. Where appropriate
(similar definitions across studies) we will pool this and report it
in the meta-analysis.
Reporting one or more of the outcomes listed here in the trial
is not an inclusion criterion for the review. We will decide study
eligibility according to the eligibility of the population studied and
the intervention evaluated.
Search methods for identification of studies
Electronic searches
Wewill identify trials through systematic searches of the following
bibliographic databases.
• Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library
• MEDLINE (Ovid)
• Embase (Ovid)
• Web of Science CPCI-S (Conference Proceedings citation
index-science).
We will adapt the preliminary search strategy for MEDLINE
(Ovid) (Appendix 1) for use in the other databases. We will ap-
ply the Cochrane sensitivity-maximising RCT filter to MED-
LINE (Ovid) (Lefebvre 2011), and adaptations of it to the other
databases, except CENTRAL.
We will also conduct a search of ClinicalTrials.gov (
www.ClinicalTrials.gov) and the World Health Organization (
WHO) International Clinical Trials Registry Platform ( ICTRP)
Search Portal ( http://apps.who.int/trialsearch/), ISRCTN Reg-
istry ( www.isrctn.com) and the European Union Clinical Tri-
als Register ( www.clinicaltrialsregister.eu) for ongoing or unpub-
lished trials.
We will search all databases from 2000 to the present and will
impose no restriction on language of publication or publication
status. Thirty-day mortality has reduced remarkably in paediatric
cardiac surgery (by around one-quarter to one-half in the UK,
the USA and Japan) (Brown 2015; Hoashi 2015; Jacobs 2016;
NICOR 2016). Studies before 2000 would be weighted dispro-
portionately because of the higher death rates. Changes in clinical
practice also make older studies less relevant to current practice.
See also Sensitivity analysis.
Wewill not performa separate search for adverse effects of corticos-
teroid use in paediatric cardiac surgery. The search strategy should
capture studies reporting beneficial or detrimental outcomes with
equal likelihood.
Searching other resources
We will check the reference lists of all included studies and any
relevant systematic reviews identified for additional references to
RCTs and will include them if eligible. We will also examine any
relevant retraction statements and errata that apply to otherwise
included studies. We will make every attempt to contact study
authors for any missing data.
Data collection and analysis
Selection of studies
Two review authors (AWLSS, KIAM) will independently screen
titles and abstracts retrieved by the literature searches to identify
potentially eligible studies, and will code them as either ‘obtain
full text’ (eligible or potentially eligible/unclear) or ‘do not ob-
tain full text’. If there are any disagreements, we will ask a third
review author to arbitrate (BCR). We will retrieve the full-text
study reports/publication and three review authors (BG, JCVS,
KIAM) will screen batches of full-text articles in teams of two re-
view authors to identify studies for inclusion. We will list all stud-
ies excluded after full-text assessment and their reasons for exclu-
sion. We will resolve any disagreement through discussion or, if
required, we will consult a fourth review author (GPG). We will
identify duplicate reports of studies and collate multiple reports of
the same study so that each study, rather than each report, is the
unit of interest in the review. We will record the selection process
in sufficient detail to complete a PRISMA flow diagram and a
‘Characteristics of excluded studies’ table.
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Data extraction and management
We will use a data collection form piloted on at least one study
included in the review to record study characteristics and outcome
data. Two review authors (DPF, JCVL) will independently extract
study characteristics from included studies. We will resolve any
differences in data extraction by discussion with a third review
author (BG). The original extraction files will be retained and a
third consensus file produced with discrepancies resolved. We will
extract the following study characteristics.
• Methods: total duration of study, number of study centres
and location, study setting, withdrawals and date of study.
• Participants: number randomised, number lost to follow-
up/withdrawn, number analysed, mean age, age range, sex,
inclusion criteria and exclusion criteria. Where reported we will
attempt to extract the underlying cardiac pathology.
• Interventions: intervention(s), comparator, concomitant
medications (by group).
• Outcomes: the primary and secondary outcomes specified
and collected, and time points at which they were reported.
• Notes: funding for trial and notable conflicts of interest of
authors of included studies.
One review author (BG) will transfer data into the Review Man-
ager 5 (RevMan 5) file (RevMan 2014).We will double-check that
data are entered correctly by comparing the data presented in the
systematic review with the study reports. A second review author
(GPG) will spot-check study characteristics for accuracy against
the reports of included studies.
Assessment of risk of bias in included studies
Two review authors (BCR, MAMA) will independently assess the
risk of bias for each included study using the ‘Risk of bias’ tool
Version 2.0 as described in Cochrane methods for individually
RCTs (Higgins 2016; see Types of studies). This is an updated
version of the tool contained in theCochrane Handbook for System-
atic Reviews of Interventions (Higgins 2017). We will resolve any
disagreements by discussion or by involving another review author
(KA). We will assess the risk of bias according to the following
domains.
• Bias arising from the randomisation process.
• Bias due to deviations from intended interventions.
• Bias due to missing outcome data.
• Bias in measurement of the outcome.
• Bias in selection of the reported result.
We intend to assess risk of bias in the effect of assignment to inter-
vention (i.e. following an intention-to-treat approach). For each
outcome, review authors’ answers to signalling questions (sup-
ported by quotes from the study where possible) will classify the
risk of bias in each domain as high, low or some concerns. The
assessment tool will also assign an overall risk of bias (across do-
mains) for the outcome. We will summarise the risk of bias judge-
ments across different studies for each of the domains, and overall,
for the outcomes assessed. We will enter review authors’ responses
to signalling questions and ‘Risk of bias’ judgements into the Ex-
cel implementation of the tool, including free-text explanations
for these responses. Where information on risk of bias relates to
unpublished data or correspondence with a trialist, we will note
this in the ‘Risk of bias’ table.
When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome (see
below: Sensitivity analysis).
Assessment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and report any deviations from it in the ‘Differences between pro-
tocol and review’ section of the review.
Measures of treatment effect
We will analyse dichotomous data as odds ratios (OR) or risk
ratios (RR) with 95% confidence intervals (CIs) and continuous
data as mean difference (MD) or standardised mean difference
(SMD) values with 95% CIs. RRs would be broadly preferred; we
can calculate these from reported numerators and denominators.
However, wemay want to analyse adjusted effects (e.g. for baseline
imbalances, which may arise in small trials). In this case, then
we will use the reported effect sizes and standard errors rather
than the reported numerators and denominators. The primary
analysis will estimate RRs using numerators and denominators. A
secondary analysis may report ORs if researchers report adjusted
analyses using ORs. We will use MD values when studies report
an outcome in consistent units. We will use SMD when studies
report an outcome in varying scales.
We will enter data presented as a scale with a consistent direction
of effect.
In the event of skewed data, we will attempt to transform data
from all studies and perform meta-analysis on the transformed
data. Where transformation of all data is not available, we will
narratively describe skewed data, preferably as medians and in-
terquartile ranges.
Unit of analysis issues
If any multi-arm studies meet the inclusion criteria of this review,
then we will merge studies where the patient has received the
intervention of prophylactic corticosteroids, regardless of specific
corticosteroid or dose. We will merge multiple follow-up times.
Dealing with missing data
We will apply standard statistical formulae to calculate missing
parameter estimates, wherever possible (e.g. using the RevMan 5
calculator to compute the standard deviation of an estimate from
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other report information such as the CI or exact P values). We
will try to contact investigators or study sponsors in order to verify
key study characteristics and obtain missing numerical outcome
data (e.g. when a study is identified only as an abstract, or when a
publication states clearly that a review outcome was measured but
is not reported). Where this is not possible, and the missing data
are thought to introduce serious bias, we will explore the impact
of including such studies in the overall assessment of results by a
Sensitivity analysis (see below).
Assessment of heterogeneity
We will use the I² statistic to describe heterogeneity among the
treatment effects included in each analysis. We will follow the
guidance outlined in Section 9.5.2 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2017)
• 0% to 40%: might not be important
• 30% to 60%: may represent moderate heterogeneity*
• 50% to 90%: may represent substantial heterogeneity*
• 75% to 100%: considerable heterogeneity*
*The importance of the observed value of the I2 statistic depends
on (i) magnitude and direction of effects and (ii) strength of evi-
dence for heterogeneity (e.g. P value from the Chi2 test, or a CI for
the I2 statistic). If our I2 statistic value indicates that heterogeneity
is a possibility and either the Tau2 is greater than zero or the P
value is low (less than 0.10), heterogeneity may be due to a factor
other than chance.
We will also assess forest plots visually for signs of heterogeneity
(i.e. by comparing CIs and directions of effect).
If we identify substantial heterogeneity (see notes on interpreting
the I2 statistic value above), we will report it and explore possible
causes by prespecified subgroup analyses (see Subgroup analysis
and investigation of heterogeneity).
If we identify major methodological or statistical heterogeneity (I2
statistic > 75% which is not reduced after exploration), we will not
pool results into a meta-analysis. Instead, we will display a forest
plot without a pooled estimate and group trials with similar pop-
ulations and interventions together to attempt to identify reasons
for heterogeneity, acknowledging that important aspects of these
elements of the research question may co-vary.
Assessment of reporting biases
For all analyses in which treatment effects from 10 or more RCTs
are synthesised, we will create and examine a funnel plot to explore
possible small study biases for the primary outcomes.
Data synthesis
Wewill undertake meta-analyses only where this is meaningful i.e.
if the treatments, participants and the underlying clinical question
are similar enough for pooling to make sense. If there is unex-
plained heterogeneity, we will display the forest plot and I2 statis-
tic, but without a pooled estimate.
We will use a random-effects model. We are evaluating a drug
treatment which should be, in principle, homogeneous and thus a
fixed-effect model could be used. In this case, however, there will
be differences in the specific drug used and the timing and dose,
plausibly introducing heterogeneity between reported treatment
effects. A random-effects model will tend to make a pooled esti-
mate more uncertain.
‘Summary of findings’ table
We will create a ‘Summary of findings’ table (see Table 1) using
the following outcomes.
• In-hospital, post-operative mortality
• Duration of post-operative mechanical ventilation
• Length of post-operative intensive care unit stay
• Length of post-operative hospital stay
The above list does not include an explicit primary harm outcome
for the reasons described above (see Types of outcome measures).
Nevertheless, important harms might be expected to be reflected
in the outcomes that steroids are hypothesised to benefit.
We will use the five GRADE considerations (study limitations,
consistency of effect, imprecision, indirectness and publication
bias) to assess the quality of a body of evidence as it relates to
the studies that contribute data to the meta-analyses for the pre-
specified outcomes. We will use methods and recommendations
described in Section 8.5 and Chapter 12 of the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2017) using
GRADEpro software (GRADEpro 2015). There is only one com-
parison (corticosteroids vs placebo) for which we will generate
‘Summary of findings’ table. We will justify all decisions to down-
grade the quality of the evidence using footnotes and we will make
comments to aid reader’s understanding of the review where nec-
essary.
Two review authors (JCVL, AWLS) will independently assess the
quality of the evidence. We will resolve any disagreements by dis-
cussion or involving a third review author (GPG). Judgements
will be justified, documented and incorporated into reporting of
results for each outcome.
We plan to extract study data, format our comparisons in data
tables and prepare a ‘Summary of findings’ table before writing
the results and conclusions of our review. A template Summary of
findings table is in the Additional tables section.
Subgroup analysis and investigation of heterogeneity
If there is sufficient data, then we will perform the following sub-
group analysis.
• Age: from birth to ≤ 30 days/from 30 days to 18 years
• Route of administration (intravenous or oral)
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• Timing of administration (preoperative, intraoperative or
postoperative)
Sensitivity analysis
We will use sensitivity analysis to assess the robustness of the re-
sults and for situations where it might affect the interpretation of
significant results. The sensitivity analysis will allow us to evalu-
ate the impact of including studies at risk of bias or missing data
such as impact of borderline decisions. We plan to carry out the
following sensitivity analyses.
• Only including studies with a low risk of bias. We will only
consider the following bias domains when classifying studies as
being at low risk of bias, or not: bias due to confounding; bias
arising from the randomisation process; bias due to deviations
from the intended interventions; bias due to missing outcome
data; bias in measurement of the outcome; bias in selection of the
reported result. With respect to bias due to deviations from the
intended interventions and bias in measurement of the outcome,
we will consider all studies to be at low risk for mortality.
• If we believe that there is large amount of missing data that
will lead to serious bias, then we will explore the impact of
including such studies by a sensitivity analysis (Dealing with
missing data).
We will assess the overall risk of bias using the ‘Risk of bias’ Version
2.0 tool (Higgins 2016). Low risk of bias is defined as ‘low risk of
bias’ in all domains for this outcome.
As described above, the improvement in cardiac surgery mortality
over the last two decadesmay lead to a decrease in mortality for the
control during the period specified by our search strategy (2000
to present, noting that surgery may have been considerably earlier
in a study published in 2000). If we observe this relationship,
a further sensitivity analysis will consider the impact of down-
weighting older studies (e.g. 2000 to 2005 versus 2006 to present)
according to themortality in the control group. To ensure that this
sensitivity analysis has reasonable power, we will need to consider
the distribution over time of participants in included RCTs as
well as changes in mortality since 2000 to set a cut-off for down-
weighting some studies. We envisage that “2000 to 2005” and
“2006 to present” may represent a reasonable split. We will use
STATA for this analysis since it allows for variable weighting of
observations in meta-analyses (“metan” command; the “iweights”
optionwill be used, specifying differential iweights for earlier (0.X)
and more recent (1.0) studies; X will be chosen as the inverse of
the ratio of the risks of the aggregate primary outcome frequencies
in early and recent studies).
Reaching conclusions
We will base our conclusions only on findings from the quanti-
tative analyses of included studies. We will avoid making recom-
mendations for practice. Similarly, implications for future research
that we report will suggest priorities based on the findings or ab-
sence of findings in relation to perceived clinical priorities. They
will also outline what the remaining uncertainties are in the area.
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A D D I T I O N A L T A B L E S
Table 1. Draft ‘Summary of findings’ table
Prophylactic corticosteroids compared with placebo/care without the use corticosteroids for paediatric cardiac surgery
Patient or population: children (aged 0 to 18 years) having cardiac surgery with cardiopulmonary bypass
Setting: hospital
Intervention: prophylactic corticosteroids
Comparison: placebo/care without the use of corticosteroids
Outcomes Anticipated absolute effects∗
(95% CI)
Relative effect
(95% CI)
Number of par-
ticipants
(studies)
Certainty of the
evidence
(GRADE)
Comments
Risk with
placebo/
care without the
use of corticos-
teroids
Risk with pro-
phylactic corti-
costeroids
In-hospital post-
operative
mortality
0 per 1000 0 per 1000
(0 to 0)
N in
(n RCTs)
Duration of me-
chanical ventila-
tion
Hours until hos-
Mean duration
was [value]
The mean dura-
tion was [value]
higher/lower
[95% CI [value]
N in
(n RCTs)
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Table 1. Draft ‘Summary of findings’ table (Continued)
pital discharge to [value]]
Length of post-
operative in-
tensive care unit
stay.
Days until hospi-
tal discharge
Mean duration
was [value]
The mean dura-
tion was [value]
higher/lower
[95% CI [value]
to [value]]
N in
(n RCTs)
Length of post-
operative hospi-
tal stay.
Days until hospi-
tal discharge.
Mean duration
was [value]
The mean dura-
tion was [value]
higher/lower
[95% CI [value]
to [value]]
N in
(n RCTs)
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect
of the intervention (and its 95% CI).
Abbreviations: CI: confidence interval; RR: risk ratio; OR: odds ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different
Low certainty: our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of
the effect
Very low certainty: we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the
estimate of effect
A P P E N D I C E S
Appendix 1. Preliminary MEDLINE (Ovid) search strategy
1. exp Adrenal Cortex Hormones/
2. (corticosteroid* or steroid*).tw.
3. corticoid*.tw.
4. exp Mineralocorticoids/
5. Mineralocorticoid*.tw.
6. Glucocorticoids/
7. Glucocorticoid*.tw.
8. Hydrocortisone/
9. Hydrocortisone*.tw.
10. Dexamethasone/
11. Dexamethasone*.tw.
12. Methylprednisolone/
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13. Methylprednisolone*.tw.
14. Prednisolone/
15. Prednisolone*.tw.
16. Prednisone/
17. Prednisone*.tw.
18. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
19. Thoracic surgery/
20. exp Cardiovascular Surgical Procedures/
21. exp cardiac surgical procedures/
22. ((cardiac or cardiol* or heart) adj2 (surgery or surgeries or surgical or procedure* or operat*)).tw.
23. Cardiopulmonary Bypass/
24. cardiopulmonary bypass.tw.
25. cpb.tw.
26. (heart adj3 bypass).tw.
27. (cardiac adj3 bypass).tw.
28. Heart Defects, Congenital/
29. 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28
30. 18 and 29
31. randomized controlled trial.pt.
32. controlled clinical trial.pt.
33. randomized.ab.
34. placebo.ab.
35. drug therapy.fs.
36. randomly.ab.
37. trial.ab.
38. groups.ab.
39. 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38
40. exp animals/ not humans.sh.
41. 39 not 40
42. 30 and 41
43. limit 42 to ed=20000101-20180814
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